CRISPR Therapeutics AG CRSP
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -34.34% | -64.80% | -89.11% | -90.59% | -81.10% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -34.34% | -64.80% | -89.11% | -90.59% | -81.10% |
| Cost of Revenue | 6.57% | 13.00% | 10.29% | 15.64% | -4.46% |
| Gross Profit | -10.45% | -20.75% | -19.65% | -25.71% | -55.09% |
| SG&A Expenses | -3.09% | -5.00% | -3.89% | 0.77% | 2.71% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.20% | 10.32% | 8.23% | 13.49% | -3.50% |
| Operating Income | -8.37% | -16.58% | -15.97% | -21.81% | -43.85% |
| Income Before Tax | 6.38% | 3.39% | -48.07% | -59.37% | -104.92% |
| Income Tax Expenses | -33.15% | -23.76% | -15.31% | 1.31% | 19.23% |
| Earnings from Continuing Operations | 6.59% | 3.56% | -47.42% | -58.80% | -103.80% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 6.59% | 3.56% | -47.42% | -58.80% | -103.80% |
| EBIT | -8.37% | -16.58% | -15.97% | -21.81% | -43.85% |
| EBITDA | -8.75% | -17.36% | -16.66% | -22.70% | -46.76% |
| EPS Basic | 14.93% | 12.20% | -37.55% | -49.46% | -99.22% |
| Normalized Basic EPS | -3.23% | -10.13% | -13.42% | -24.37% | -60.35% |
| EPS Diluted | 15.06% | 12.22% | -37.66% | -49.40% | -97.13% |
| Normalized Diluted EPS | -3.23% | -10.13% | -13.42% | -24.37% | -59.04% |
| Average Basic Shares Outstanding | 9.95% | 10.31% | 8.24% | 6.57% | 5.47% |
| Average Diluted Shares Outstanding | 9.95% | 10.31% | 8.24% | 6.57% | 4.95% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |